Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Tamoxifen and raloxifene have been shown to reduce the risk of breast cancer in women with a higher-than-average risk, but these drugs can have their own risks and side effects. Tamoxifen and raloxifene are the only drugs approved in the US to help lower the risk of breast cancer, although for some women, other drugs called aromatase inhibitors might be an option as well.
Both of these drugs are selective estrogen receptor modulators (SERMs). This means that they act against (or block) estrogen (a female hormone) in some tissues of the body, but act like estrogen in others. Estrogen can fuel the growth of breast cancer cells. Both of these drugs block estrogen in breast cells, which is why they can be useful in lowering breast cancer risk.
These drugs are used more often for other reasons.
When used to lower the risk of breast cancer, these drugs are typically taken for 5 years. Both drugs are pills taken once a day. Tamoxifen also comes in a liquid form.
Tamoxifen can be an option whether or not you have gone through menopause, but raloxifene is only approved for post-menopausal women.
To learn more about who should (and should not) consider taking one of these drugs, see Deciding Whether to Use Medicine to Reduce Breast Cancer Risk.
The effect of these drugs on breast cancer risk has varied in different studies. When the results of all the studies are taken together, the overall reduction in risk for these drugs is about 40% (more than a third).
Although a medicine that cuts your risk by about 40% sounds like it must be a good thing, what it means for you depends on how high your risk is in the first place (your baseline risk).
For example, if you had a 5% risk of getting breast cancer in the next 5 years, you would be considered at increased risk. A 5% risk would mean that over the next 5 years, 5 of 100 women with your risk would be expected to get breast cancer. A 40% reduction in your risk would mean your risk goes down to 3%. This would be a 2% change overall.
Since the change in your overall risk depends on your baseline risk, you would benefit less if you had a lower baseline risk, and you would benefit more if your risk was higher. If you had a baseline risk of only 1.7% in the next 5 years (which is what many expert groups use as a cutoff point for being at 'increased risk'), a 40% change would mean that your risk would go down by less than 1% overall (to about 1%) in the next 5 years.
Your doctor can estimate your breast cancer risk based on factors like your age, medical history, and family history. This can help you see how much benefit you might get from taking one of these drugs.
Both tamoxifen and raloxifene can help prevent osteoporosis, a severe weakening of the bones that can increase the risk of bone fractures and is more common after menopause.
The most common side effects of these drugs are symptoms of menopause. These include hot flashes and night sweats. Tamoxifen can also cause vaginal dryness and vaginal discharge. Pre-menopausal women taking tamoxifen can have menstrual changes. Menstrual periods can become irregular or even stop. Although periods often start again after the drug is stopped, they don’t always, and some women go into menopause. This is more likely in women who were close to menopause when they started taking the drug.
Other, more serious side effects are rare. These include serious blood clots and cancer of the uterus.
Both tamoxifen and raloxifene increase your risk of developing blood clots in a vein in your leg (deep venous thrombosis) or in your lungs (pulmonary embolism). These clots can sometimes cause serious problems, and even death. In the major studies looking at these drugs for breast cancer prevention, the overall risk of these blood clots over 5 years of treatment was less than 1%. This risk could be higher if you had a serious blood clot in the past, so these drugs are generally not recommended to lower breast cancer risk for anyone with a history of blood clots.
Because these drugs increase your risk of developing serious blood clots, there is also concern that they might also increase your risk of heart attack or stroke, although this is not clear. You might want to discuss this with your doctor, especially if you have a history of a heart attack or stroke, or if you are at increased risk for them. (See Deciding Whether to Use Medicine to Reduce Breast Cancer Risk.)
Because tamoxifen acts like estrogen in the uterus, it can increase your risk of cancers of the uterus, including endometrial cancer and uterine sarcoma. It's also linked to a higher risk of endometrial pre-cancers. The increased risk seems to affect women over 50, but not younger women.
The overall increase in the risk of uterine cancer with tamoxifen use is low (less than 1%), and it goes back to normal within a few years of stopping the drug.
If you have had a hysterectomy (surgery to remove the uterus), you are not at risk for endometrial cancer or uterine sarcoma and do not have to worry about these cancers.
If you are taking tamoxifen, tell your doctor if you have any abnormal vaginal bleeding or spotting, especially after menopause, as these are possible symptoms of uterine cancer.
Raloxifene does not act like estrogen in the uterus and is not linked to an increased risk of uterine cancer.
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Cuzick J, Sestak I, Bonanni B, et al; for the SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data. Lancet. 2013;381:1827-1834.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–1662.
King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251-2256.
Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Medication use for the risk reduction of primary breast cancer in women: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;322(9):868-886.
National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Breast Cancer Risk Reduction. V.1.2021. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf on September 23, 2021.
Sharma P. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention.
UpToDate. 2021. Accessed at https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention on September 23, 2021.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, et al. Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019;322(9):857-867.
Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(33):3152-3165.
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–2741.
Last Revised: December 16, 2021